Rigel Pharmaceuticals (RIGL)
(Delayed Data from NSDQ)
$7.73 USD
-0.69 (-8.19%)
Updated Jul 3, 2024 01:00 PM ET
After-Market: $7.70 -0.03 (-0.39%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth F Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RIGL 7.73 -0.69(-8.19%)
Will RIGL be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for RIGL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RIGL
Rigel (RIGL) Upgraded to Buy: Here's What You Should Know
Rigel Pharmaceuticals (RIGL) Reports Q1 Loss, Lags Revenue Estimates
RIGL: What are Zacks experts saying now?
Zacks Private Portfolio Services
ProPhase Labs, Inc. (PRPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Tops Revenue Estimates
Rigel Pharmaceuticals (RIGL) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Other News for RIGL
Biotech Alert: Searches spiking for these stocks today
Optime Care Announces Enhanced Partnership with Rigel Pharmaceuticals for GAVRETO® Patients
Rigel Pharmaceuticals trading halted, news pending
Rigel Announces Reverse Stock Split
Rigel announces reverse stock split